User login
Until recently, atopic dermatitis was considered a childhood disease that was self-limited over a few years. Emerging studies have shown that the burden of atopic dermatitis includes potential cardiac disease in adulthood, comorbidities including allergy and psychological disorders, and possible superinfection complications.
Dr Lawrence F. Eichenfield, chief of the department of pediatric and adolescent dermatology at Rady Children's Hospital, reports on biological, systemic, and topical treatments either currently in use or being studied for children suffering from atopic dermatitis. These studies include both steroid and steroid-sparing topical agents, a novel AhR modulating agent, as well as JAK inhibitors that are under active investigation.
--
Lawrence F. Eichenfield, MD, Distinguished Professor; Vice Chair, Department of Dermatology and Pediatrics, University of California, San Diego; Chief, Department of Pediatric and Adolescent Dermatology, Rady Children's Hospital, San Diego, California.
Lawrence F. Eichenfield, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AbbVie; Dermavant; Dermira; Forte Biosciences; Galderma Laboratories; Incyte; Leo Pharma; Eli Lilly and Company; Otsuka; Novartis; Pfizer. Serve(d) as a speaker or a member of a speakers bureau for: Regeneron; Sanofi-Genzyme; Pfizer. Received research grant from: AbbVie; Regeneron; Sanofi Genzyme; Ortho Dermatology. Serve(d) on the data safety monitoring board for: Asana; Glenmark/Ichnos.
Until recently, atopic dermatitis was considered a childhood disease that was self-limited over a few years. Emerging studies have shown that the burden of atopic dermatitis includes potential cardiac disease in adulthood, comorbidities including allergy and psychological disorders, and possible superinfection complications.
Dr Lawrence F. Eichenfield, chief of the department of pediatric and adolescent dermatology at Rady Children's Hospital, reports on biological, systemic, and topical treatments either currently in use or being studied for children suffering from atopic dermatitis. These studies include both steroid and steroid-sparing topical agents, a novel AhR modulating agent, as well as JAK inhibitors that are under active investigation.
--
Lawrence F. Eichenfield, MD, Distinguished Professor; Vice Chair, Department of Dermatology and Pediatrics, University of California, San Diego; Chief, Department of Pediatric and Adolescent Dermatology, Rady Children's Hospital, San Diego, California.
Lawrence F. Eichenfield, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AbbVie; Dermavant; Dermira; Forte Biosciences; Galderma Laboratories; Incyte; Leo Pharma; Eli Lilly and Company; Otsuka; Novartis; Pfizer. Serve(d) as a speaker or a member of a speakers bureau for: Regeneron; Sanofi-Genzyme; Pfizer. Received research grant from: AbbVie; Regeneron; Sanofi Genzyme; Ortho Dermatology. Serve(d) on the data safety monitoring board for: Asana; Glenmark/Ichnos.
Until recently, atopic dermatitis was considered a childhood disease that was self-limited over a few years. Emerging studies have shown that the burden of atopic dermatitis includes potential cardiac disease in adulthood, comorbidities including allergy and psychological disorders, and possible superinfection complications.
Dr Lawrence F. Eichenfield, chief of the department of pediatric and adolescent dermatology at Rady Children's Hospital, reports on biological, systemic, and topical treatments either currently in use or being studied for children suffering from atopic dermatitis. These studies include both steroid and steroid-sparing topical agents, a novel AhR modulating agent, as well as JAK inhibitors that are under active investigation.
--
Lawrence F. Eichenfield, MD, Distinguished Professor; Vice Chair, Department of Dermatology and Pediatrics, University of California, San Diego; Chief, Department of Pediatric and Adolescent Dermatology, Rady Children's Hospital, San Diego, California.
Lawrence F. Eichenfield, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AbbVie; Dermavant; Dermira; Forte Biosciences; Galderma Laboratories; Incyte; Leo Pharma; Eli Lilly and Company; Otsuka; Novartis; Pfizer. Serve(d) as a speaker or a member of a speakers bureau for: Regeneron; Sanofi-Genzyme; Pfizer. Received research grant from: AbbVie; Regeneron; Sanofi Genzyme; Ortho Dermatology. Serve(d) on the data safety monitoring board for: Asana; Glenmark/Ichnos.
